Background：Elezanumab is a fully humanized monoclonal antibody directed against repulsive guidance molecule A RGMa. Studies in patients with multiple sclerosis MS demonstrate RGMa upregulation, which inhibits axonal growth and myelination, oligodendroglial regeneration and functional recovery after trauma or inflammation. Elezanumab treatment promoted axon regeneration, neuroprotection, remyelination, and immune modulation in several MS-relevant preclinical models. Elezanumab was previously well-tolerated as a single dose to healthy volunteers.
Alternative Names：ABT-555, AE12-1Y-QL derived from parental mAb AE12-1 and AE12-1Y,
